Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263717 | 1.00 | SMYD3 (0.57) | SMYD3MCHR1ADRA2AHRH1HTR2B | |
| SCHEMBL4266600 | 0.86 | RAB9A (0.59) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4266604 | 0.86 | RAB9A (0.59) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4260501 | 0.84 | SMYD3 (0.57) | SMYD3MCHR1ADRA2AHRH1HTR2B | |
| SCHEMBL4260496 | 0.84 | SMYD3 (0.57) | SMYD3MCHR1ADRA2AHRH1HTR2B | |
| SCHEMBL4263766 | 0.83 | MCHR1 (0.60) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4263772 | 0.83 | MCHR1 (0.60) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL6462903 | 0.82 | MCHR1 (0.78) | SMYD3MCHR1ADRA2AHRH1HTR2B | |
| SCHEMBL6462910 | 0.82 | MCHR1 (0.78) | SMYD3MCHR1ADRA2AHRH1HTR2B | |
| SCHEMBL4270965 | 0.82 | MCHR1 (0.56) | MCHR1ADRA2AHRH1HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | SMYD3 861/4885MCHR1 3/4885ADRA2A 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.